Fuseworks Media

BioOra, the Kiwi biotech leading the fight in immune cell cancer therapy

A pioneering New Zealand medical innovator, BioOra, is to embark on a capital raise to accelerate its groundbreaking automated platform that reprograms blood cells to fight cancer.

The therapy is truly personalised where BioOra uses a patient’s own immune cells (T-cells) and reprograms them in the laboratory to directly identify and kill cancer cells once reinfused back into the patient.

“We insert a receptor into the immune cells so that they only recognise the cancer cells in the patient’s body. The T-cells then circulate in the body, attack and kill any cancer cells they find,” BioOra CEO Andi Grant says.

The startup is the only licensed manufacturer of chimeric antigen receptor (CAR-T) cell therapeutics in New Zealand and has a vision of, ‘Cell therapy for every patient in need’. Its goal is to democratise access to these treatments. Its automated technology is the means to do that effectively and efficiently.

Grant says BioOra is also one of the first companies in the world outside large overseas pharmaceutical companies to create an automated platform to manufacture CAR-T cells. Automating the process provides significant advantages including increased throughput and lower costs, while maintaining quality.

“We are leading; we’re at the forefront, we are one of those kiwi innovators that is punching above its weight,” Grant says. “Whilst nothing is ever a panacea, we’ve seen cancer patients who have run out of treatment options going into complete remission with therapies that are available overseas.”

BioOra was formed in 2021 by the Malaghan Institute of Medical Research and Bridgewest Ventures as part of Callaghan Innovation’s Technology Incubator Programme. Callaghan Innovation provided BioOra with access to investment funding through their programme, and Bridgewest provided investment capital and wrap-around services to support the growth of the company. The Malaghan Institute was the original founder of the technology, and their therapies will be the first to be delivered to patients using the BioOra platform.

Until now, CAR-T cells have been produced using a time-intensive manual process requiring many hours of skilled operator time inside one specialised clean room for each patient’s dose. BioOra changes that.

“What we have developed is a closed, automated process where we can run multiple patients’ products in the same room, and because the process is automated, we reduce the amount of skilled labour hours required for one patient’s dose. All of this means more patients are treated at a lower cost per patient,” Grant explains.

“BioOra is applying smart, digital, decentralised and automated clinical and manufacturing approaches here in New Zealand. The goal, first and foremost, is to ensure affordable access to therapies for New Zealanders. We also see enormous commercial opportunity in licensing our process and platforms globally to other partners who want to treat the maximum number of patients and rapidly grow their market share.”


Powered by Fuseworks and Truescope - Media monitoring, insights and news distribution for New Zealand organisations.